期刊文献+

肺癌患者介入治疗前后凝血、纤溶及血小板功能的变化 被引量:3

Alternation of Blood Coagulation,Fibrinolytic and Platelet Function Before and After the Interventional Therapy of Primary Pulmonary Carcinoma
下载PDF
导出
摘要 目的研究原发性支气管肺癌介入治疗前(A1组)、后(A2组)凝血及纤溶功能的变化。方法比较A1组(52例)、A2组(52例)及30例对照组(B组)指标。PT、aPTT、TT、Fbg、FⅦ、FⅧ、FⅩ采用光散射比浊法,P-选择素(Ps),血管性血友病因子(vWF),尿激酶型纤溶酶原激活物(uPA)采用ELISA法,uPA抑制物(PAI)采用发色底物法测定。结果1.与B组比较,A1组aPTT、TT、Fbg、FⅧ、Ps、vWF、uPA和PAI均升高(P<0.05~0.01)。2.与A1组比较,A2组Fbg、FⅧ、Ps、uPA和PAI降低(P<0.05~0.01)。结论原发性支气管肺癌患者凝血及纤溶过度激活,血小板活化,介入治疗后减轻。 Objective To terventional therapy of primary study the changes of blood coagulation and fibrinolytic function before the inpulmonary carcinama (group A1 ) and after that ( group A2) . Methods To analyze PT, aPTT, TF, Fbg, F Ⅶ, F Ⅷ, F X in group A1 ( n = 52 ), group A2 ( n = 52 ) and control group (group B n = 30) with the light scattering turbidimetry, and P-selectin (Ps), you Willebrand factor (vWF), urokinase profibrinolytic activating factor (uPA) were examined by ELISA, and uPA' s inhibitor (PAl) with chromogenic substracte. Results aPTT , TT,Fbg,FⅧ,Ps,vWF,uPA and PAl in group A1 were higher than those in group B(P 〈0.05 -0.01 ). Fg,FⅧ,Ps,uPA and PAI in group A2 were less than those in group A1 ( P 〈 0.05 - 0.01 ). Conclusion The blood coagulation and fibrinolytic function of primary pulmonary carcinoma were over activated, platelet was animated, and abated after interventional therapy
出处 《血栓与止血学》 2009年第2期65-67,共3页 Chinese Journal of Thrombosis and Hemostasis
基金 广东省珠海市重大科技立项资助项目(PC20061097)
关键词 原发性支气管肺癌 介入治疗 凝血 纤溶 血小板 Primary pulmonary carcinoma Interventional therapy Blood coagulation Fibrinolysis Platelet.
  • 相关文献

参考文献4

二级参考文献23

  • 1王兆钺,王山喜,阮长耿.11-去氢-血栓烷B_2测定及其临床应用[J].中华血液学杂志,1996,17(9):472-474. 被引量:20
  • 2包承鑫 李家增 等.恶性肿瘤与血栓形成.血栓病学[M].北京:科学出版社,1998.243-247.
  • 3韩锐,肿瘤化学预防及药物治疗,1991年
  • 4李振,恶性肿瘤的化学治疗与免疫治疗,1990年
  • 5叶应妩,临床实验诊断学.上,1989年
  • 6王振义,中华血液学杂志,1981年,2卷,105页
  • 7Robert L, Cohen M, Xi XP, et al, Effects of urokinase receptorn occupancy on plasmin generation and proteolysis of basement by human cells, Blood, 1991,78(2):479-487.
  • 8Liotta LA, Goldfarb RH. Effect of plasminogen activator(urokianse), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res,1981,41:4629-4636.
  • 9Stefansson S, Kounnas MZ, Henkin J, et al. Gp330 on type Ⅱ pneumocytes mediates endocytosis leading to degradation of prourokinase plasminogen activator inhibitor-1 and urokinaseplasminogen activator inhibitor-1 complex, J Cell Sci, 1991,108(Pt6):2361-2368.
  • 10Pyke C, Kristensen P, Ralfkiaer E, et al. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the turnor stroma. Cancer Res, 1991,51:4067-4071.

共引文献91

同被引文献36

  • 1张爱华,孙达春,李小亮,彭秀斌,梁翠微,周志伟.介入治疗对原发性支气管肺癌患者凝血及纤溶功能的影响[J].国外医学(临床生物化学与检验学分册),2005,26(3):131-132. 被引量:2
  • 2Louzada ML, Majeed H, Dao V, et al. Risk of recurrent venous thromboembolism according to malignancy characteristics in pa-tients with cancer - associated thrombosis : A systematic review of observational and intervention studies[ J]. Blood Coagul Fibrlnoly- sis,2011,22(2) :86 -91.
  • 3Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D - dimer plasma levels in response and progressive disease in pa- tients with lung cancer [ J ]. Lung Cancer,2006,53 ( 2 ) : 205 - 210.
  • 4Buccher G, Torchio P, Ferrigno D. Plasma levels of D - dimer in lung carcinoma:Clinical and prognostic significance[J]. Cancer, 2003.97(12) :3044 -3052.
  • 5Ay C,Simanek R,Vormittag R,et al.High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients:results from the Vienna Cancer and Thrombosis Study(CATS)[J].Blood,2008,112(7):2703-2708.
  • 6Khorana A A,Francis C W,Culakova E,et al.Frequency,risk factors,and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,110(10):2339-2346.
  • 7Chen H T,Tsou H K,Tsai C H,et al.Thromb in enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway[J].Cell Physiol,2010,223(3):737-745.
  • 8Paskauskas S,Pundzius J,Barauskas G.Venous thromboembolism and prophylaxis in cancer patients[J].Medicina(Kaunas),2008,44(3):175-181.
  • 9Lyman GH,Khorana AA.Cancer,clots and consensus:new under- standing of an old problem[J].J Clin Oncol,2009,27(29):4821-4826.
  • 10Zhang X,Liu ZQ,Zhang W,et al.A retrospective analysis of plas- ma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression[J].Int J Clin Exp Med,2014,7(8):2395-2401.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部